Published in Liver Transpl on April 09, 2013
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med (2005) 4.27
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 3.57
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology (2008) 3.52
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol (2009) 3.43
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med (2012) 2.62
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35
Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases. Liver Transpl (2007) 2.31
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol (2008) 2.15
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol (2006) 2.10
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
National survey of provider opinions on controversial characteristics of liver transplant candidates. Liver Transpl (2013) 2.00
Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol (2011) 1.89
Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA (2010) 1.84
Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol (2006) 1.68
Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol (2011) 1.62
Colon cancer, version 3.2014. J Natl Compr Canc Netw (2014) 1.59
Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer. Ann Surg (2013) 1.56
Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology (2010) 1.55
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol (2007) 1.51
Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. Liver Transpl (2014) 1.50
Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J Hepatol (2009) 1.50
Effects of large hiatal hernias on esophageal peristalsis. Arch Surg (2012) 1.49
Rectal cancer. J Natl Compr Canc Netw (2012) 1.49
Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol (2013) 1.47
Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology (2008) 1.45
Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology (2009) 1.44
Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol (2009) 1.43
Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials. J Vasc Interv Radiol (2013) 1.41
National survey of adult transplant hepatologists on the pediatric-to-adult care transition after liver transplantation. Liver Transpl (2015) 1.41
Gastric cancer. J Natl Compr Canc Netw (2010) 1.35
Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol (2008) 1.33
Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 1.31
90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg (2008) 1.30
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol (2010) 1.25
Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology (2011) 1.25
Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics (2008) 1.25
A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring. J Vasc Interv Radiol (2007) 1.23
Effect of C-arm angiographic CT on transcatheter arterial chemoembolization of liver tumors. J Vasc Interv Radiol (2007) 1.20
Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol (2008) 1.19
Transcatheter intraarterial perfusion: MR monitoring of chemoembolization for hepatocellular carcinoma--feasibility of initial clinical translation. Radiology (2008) 1.19
Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol (2009) 1.18
Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 1.17
Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol (2009) 1.17
Operative risk of total hip and knee arthroplasty in cirrhotic patients. J Arthroplasty (2005) 1.15
Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer (2008) 1.14
Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol (2013) 1.08
Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1alpha in rabbit VX2 liver tumors. J Vasc Interv Radiol (2007) 1.07
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res (2012) 1.07
Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol (2012) 1.06
Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol (2008) 1.03
Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol (2008) 1.03
Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol (2007) 1.02
Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol (2013) 1.02
Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys (2011) 1.01
Comparison between intravenous and intraarterial contrast injections for dynamic 3D MRI of liver tumors in the VX2 rabbit model. J Magn Reson Imaging (2006) 1.01
NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw (2010) 1.00
In vivo diffusion-weighted imaging of liver tumor necrosis in the VX2 rabbit model at 1.5 Tesla. Invest Radiol (2006) 1.00
Four-dimensional transcatheter intraarterial perfusion MR imaging for monitoring chemoembolization of hepatocellular carcinoma: preliminary results. J Vasc Interv Radiol (2008) 1.00
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 0.99
Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival. J Vasc Interv Radiol (2009) 0.98
Magnetic resonance elastography and biomarkers to assess fibrosis from recurrent hepatitis C in liver transplant recipients. Transplantation (2011) 0.97
Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging (2009) 0.97
Colon cancer. J Natl Compr Canc Netw (2011) 0.96
Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol (2012) 0.96
Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol (2006) 0.96
Overview of immunosuppression in liver transplantation. World J Gastroenterol (2009) 0.96
Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 0.96
Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World J Gastroenterol (2010) 0.95
Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl (2005) 0.95
Genomic biomarkers correlate with HLA-identical renal transplant tolerance. J Am Soc Nephrol (2013) 0.94
Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma. J Magn Reson Imaging (2010) 0.94
Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) (2005) 0.94
Esophageal cancer. J Natl Compr Canc Netw (2008) 0.93
A prospective, randomized, double-blind, placebo-controlled trial of retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy. Dis Colon Rectum (2005) 0.93
Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging (2014) 0.91
Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys (2011) 0.91
Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients. Hepatology (2012) 0.91
Medication misuse, nonadherence, and clinical outcomes among liver transplant recipients. Liver Transpl (2015) 0.90
Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer (2013) 0.88
Emerging approaches in hepatocellular carcinoma. J Clin Gastroenterol (2007) 0.88
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation (2015) 0.88
Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. Transplantation (2010) 0.88
Hepatic abscess after yttrium-90 radioembolization for islet-cell tumor hepatic metastasis. Cardiovasc Intervent Radiol (2009) 0.88
Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol (2010) 0.87
Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys (2010) 0.86
Feasibility of blood oxygenation level-dependent MR imaging to monitor hepatic transcatheter arterial embolization in rabbits. J Vasc Interv Radiol (2005) 0.85
Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States. Ann Surg Oncol (2012) 0.84
Morphological analysis of pancreatic adenocarcinoma on multidetector row computed tomography: implications for treatment response evaluation. Pancreas (2009) 0.84
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.83
Acid-base and potassium disorders in liver disease. Semin Nephrol (2006) 0.83
Association of hepatic artery stenosis and biliary strictures in liver transplant recipients. Liver Transpl (2011) 0.82
MRI-guided biopsy to correlate tissue specimens with MR elastography stiffness readings in liver transplants. Acad Radiol (2012) 0.82
Phase II Trial of Docetaxel and Carboplatin in Patients With Advanced Squamous Carcinoma of the Esophagus (E2298): A Trial of the Eastern Cooperative Oncology Group. Gastrointest Cancer Res (2011) 0.82
Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: results from a pilot study. J Vasc Interv Radiol (2009) 0.82
Hepatotoxicity and drug interactions in liver transplant candidates and recipients. Clin Liver Dis (2013) 0.82